Skip to main content
NEWLAND PHARMACEUTICAL CO., LTD logo

NEWLAND PHARMACEUTICAL CO., LTD — Investor Relations & Filings

Ticker · 301277 ISIN · CNE1000065K2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2024-04-23 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 301277

About NEWLAND PHARMACEUTICAL CO., LTD

https://www.newlandpharma.com

Newland Pharmaceutical Co., Ltd. is a specialized enterprise engaged in the research, development, manufacturing, and global distribution of active pharmaceutical ingredients (APIs) and high-quality chemical intermediates. The company focuses on a broad spectrum of therapeutic categories, including cardiovascular, anti-infective, and metabolic health solutions. Operating with a commitment to rigorous quality control, its production facilities are designed to meet international Good Manufacturing Practice (GMP) standards. Newland Pharmaceutical prioritizes technological innovation and chemical synthesis optimization to deliver reliable pharmaceutical components. Its core operations involve the large-scale production of complex molecules, supporting the supply chains of healthcare providers and pharmaceutical formulators worldwide through a focus on technical excellence and regulatory compliance.

Recent filings

Filing Released Lang Actions
第六届监事会第一次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the company's sixth supervisory board meeting. It mentions the approval of the 2024 first quarter report but does not contain the report itself; instead, it refers readers to the full report published on an external website. The document also includes election results for the supervisory board chairman. The length is short (1244 characters), and the content is primarily about meeting resolutions and announcements rather than the full financial report. Therefore, it fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not contain substantive financial data or the full report itself.
2024-04-23 Chinese
第六届董事会第一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the first meeting of the sixth board of directors of the company, including election of board chairman, vice chairman, committee members, and appointment of senior management. It references the 2024 first quarter report but does not contain the report itself, only mentions that the report is disclosed elsewhere. The document also includes voting results and procedural compliance statements. This fits the category of Board/Management Information (MANG) as it primarily announces changes in the company's board and senior management rather than being a financial report or other type of filing.
2024-04-23 Chinese
董事会审计委员会对会计师事务所2023年度履职情况评估及履行监督职责情况报告
Audit Report / Information Classification · 95% confidence The document is a detailed report from the Board Audit Committee evaluating the performance and supervision of the accounting firm (auditor) for the fiscal year 2023. It discusses the auditor's qualifications, audit scope, communication with management, and the audit results including the issuance of an unqualified audit opinion on the 2023 financial statements. The document references the audit of the 2023 annual financial report and internal controls but does not contain the financial statements themselves. It is a standalone audit-related report focusing on the auditor's performance and supervisory activities rather than the full annual report or the audit report itself. The length is under 5,000 characters, but the content is substantive and not merely an announcement. This fits the definition of an Audit Report / Information (AR) filing, which includes standalone audit reports and related supervisory evaluations, excluding full annual reports. FY 2023
2024-04-23 Chinese
北京市天元律师事务所关于新天地药业股份有限公司2023年年度股东大会的法律意见
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the 2023 Annual General Meeting (AGM) of a company. It details the procedures of the AGM, the qualifications of attendees, the voting process, and the results of various resolutions including approval of the 2023 annual report, board and supervisory reports, financial statements, profit distribution plan, remuneration, and election of board members. The document is focused on the AGM event and its legal compliance rather than the annual report itself or financial data. It is not a full annual report (10-K) or an earnings release, but a legal opinion related to the AGM. Therefore, the document fits best into the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports official voting results from the AGM.
2024-04-23 Chinese
2023年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as the "2023 Annual General Meeting Resolution Announcement" of 新天地药业股份有限公司. It details the resolutions passed at the 2023 Annual General Meeting (AGM), including approval of the 2023 annual report, board and supervisory reports, financial statements, profit distribution plan, remuneration, and election of board and supervisory members. It also includes voting results and legal opinions on the meeting's validity. The document is a formal announcement of the AGM resolutions and voting outcomes, not the full annual report or financial statements themselves. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (6897 characters) and content confirm it is a detailed voting result announcement rather than a brief report publication notice or the report itself.
2024-04-23 Chinese
关于2024年第一季度报告披露的提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (262 characters) indicating that the company's 2024 first quarter report has been published and is available on a website. It does not contain the actual financial data or substantive analysis from the quarterly report itself, but rather directs investors to where the report can be found. This fits the criteria for a Report Publication Announcement (RPA) rather than an Interim/Quarterly Report (IR).
2024-04-23 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.